Details
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 12326-12337 |
Seitenumfang | 12 |
Fachzeitschrift | Chemistry - A European Journal |
Jahrgang | 23 |
Ausgabenummer | 50 |
Frühes Online-Datum | 6 Juni 2017 |
Publikationsstatus | Veröffentlicht - 7 Sept. 2017 |
Abstract
Conjugates based on nanostructured, superparamagnetic particles, a thermolabile linker and a cytotoxic maytansinoid were developed to serve as a model for tumour-selective drug delivery and release. It combines chemo- with thermal therapy. The linker-modified toxin was prepared by a combination of biotechnology and semisynthesis. Drug release was achieved by hyperthermia through an external oscillating electromagnetic field that induces heat inside the particles. Efficacy of this release concept was demonstrated both for cancer cell proliferation in vitro, and for tumour growth in vivo, in a xenograft mouse model. Biocompatibility studies for these magnetic-nanoparticle/ansamitocin conjugates complement this work.
ASJC Scopus Sachgebiete
- Chemische Verfahrenstechnik (insg.)
- Katalyse
- Chemie (insg.)
- Organische Chemie
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Chemistry - A European Journal, Jahrgang 23, Nr. 50, 07.09.2017, S. 12326-12337.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Synthesis of Magnetic-Nanoparticle/Ansamitocin Conjugates
T2 - Inductive Heating Leads to Decreased Cell Proliferation In Vitro and Attenuation Of Tumour Growth In Vivo
AU - Seidel, Katja
AU - Balakrishnan, Asha
AU - Alexiou, Christoph
AU - Janko, Christina
AU - Komoll, Ronja Melinda
AU - Wang, Liangliang
AU - Kirschning, Andreas
AU - Ott, Michael
N1 - Funding information: The work was funded by the Deutsche Forschungsgemeinschaft (Cluster of Excellence REBIRTH; “From Regenerative Biology to Reconstructive Therapy” EXC 62, the Cluster of Excellence EAM; “Engineering of Advanced Materials” EXC 315 and AL 552/8-1), the Ministry of Science and Culture of Lower Saxony (MWK; graduate school HSN) and the Bavarian State Ministry for the Environment and Consumer Protection. We thank H. Herzog and Prof. S. Katusic (EVONIK Industries, AG, Essen, Germany) for technical advice. We are grateful to N. C. Bigall and J. F. Miethe (institute of physical chemistry, Leibniz University Hannover) for carrying out transmission electron microscopy measurements (TEM) (see Supporting Information). Animal experiments have been approved by local authorities under AZ 33.19-42502-04-14/1662 (Niedersächsiches Landesamt für Verbraucherschutz und Lebensmittelsicherheit). The work was funded by the Deutsche Forschungsgemeinschaft (Cluster of Excellence REBIRTH; ?From Regenerative Biology to Reconstructive Therapy? EXC 62, the Cluster of Excellence EAM; ?Engineering of Advanced Materials? EXC 315 and AL 552/8-1), the Ministry of Science and Culture of Lower Saxony (MWK; graduate school HSN) and the Bavarian State Ministry for the Environment and Consumer Protection. We thank H. Herzog and Prof. S. Katusic (EVONIK Industries, AG, Essen, Germany) for technical advice. We are grateful to N. C. Bigall and J. F. Miethe (institute of physical chemistry, Leibniz University Hannover) for carrying out transmission electron microscopy measurements (TEM) (see Supporting Information). Animal experiments have been approved by local authorities under AZ 33.19-42502-04-14/1662 (Nieders?chsiches Landesamt f?r Verbraucherschutz und Lebensmittelsicherheit).
PY - 2017/9/7
Y1 - 2017/9/7
N2 - Conjugates based on nanostructured, superparamagnetic particles, a thermolabile linker and a cytotoxic maytansinoid were developed to serve as a model for tumour-selective drug delivery and release. It combines chemo- with thermal therapy. The linker-modified toxin was prepared by a combination of biotechnology and semisynthesis. Drug release was achieved by hyperthermia through an external oscillating electromagnetic field that induces heat inside the particles. Efficacy of this release concept was demonstrated both for cancer cell proliferation in vitro, and for tumour growth in vivo, in a xenograft mouse model. Biocompatibility studies for these magnetic-nanoparticle/ansamitocin conjugates complement this work.
AB - Conjugates based on nanostructured, superparamagnetic particles, a thermolabile linker and a cytotoxic maytansinoid were developed to serve as a model for tumour-selective drug delivery and release. It combines chemo- with thermal therapy. The linker-modified toxin was prepared by a combination of biotechnology and semisynthesis. Drug release was achieved by hyperthermia through an external oscillating electromagnetic field that induces heat inside the particles. Efficacy of this release concept was demonstrated both for cancer cell proliferation in vitro, and for tumour growth in vivo, in a xenograft mouse model. Biocompatibility studies for these magnetic-nanoparticle/ansamitocin conjugates complement this work.
KW - antitumour agents
KW - biotransformations
KW - in vivo studies
KW - iron
KW - maytansin
KW - nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85026473793&partnerID=8YFLogxK
U2 - 10.1002/chem.201701491
DO - 10.1002/chem.201701491
M3 - Article
C2 - 28585348
AN - SCOPUS:85026473793
VL - 23
SP - 12326
EP - 12337
JO - Chemistry - A European Journal
JF - Chemistry - A European Journal
SN - 0947-6539
IS - 50
ER -